New York State Common Retirement Fund
CRNX

New York State Common Retirement Fund’s Crinetics Pharmaceuticals CRNX Stock Holding History

New York State Common Retirement Fund’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.51M Buy
147,218
+5,600
+4% +$208K 0.01% 1039
2026
Q1 		$5.14M Sell
141,618
-4,505
-3% -$201K 0.01% 1009
2025
Q4 		$6.8M Sell
146,123
-2,154
-1% -$95.9K 0.01% 908
2025
Q3 		$6.18M Buy
148,277
+7,359
+5% +$235K 0.01% 969
2025
Q2 		$4.05M Buy
140,918
+3,000
+2% +$92.6K 0.01% 1146
2025
Q1 		$4.63M Sell
137,918
-17,508
-11% -$654K 0.01% 1088
2024
Q4 		$7.95M Buy
155,426
+7,735
+5% +$433K 0.01% 896
2024
Q3 		$7.55M Sell
147,691
-19,051
-11% -$983K 0.01% 922
2024
Q2 		$7.47M Buy
166,742
+14,250
+9% +$658K 0.01% 945
2024
Q1 		$7.14M Buy
152,492
+124,767
+450% +$4.88M 0.01% 962
2023
Q4 		$986K Buy
27,725
+44
+0.2% +$1.35K ﹤0.01% 1802
2023
Q3 		$823K Buy
27,681
+4,942
+22% +$102K ﹤0.01% 1844
2023
Q2 		$410K Sell
22,739
-6,025
-21% -$120K ﹤0.01% 2182
2023
Q1 		$462K Sell
28,764
-10,356
-26% -$192K ﹤0.01% 2218
2022
Q4 		$716K Sell
39,120
-28
-0.1% -$493 ﹤0.01% 2142
2022
Q3 		$769K Buy
39,148
+5,156
+15% +$105K ﹤0.01% 2098
2022
Q2 		$634K Buy
33,992
+2,571
+8% +$51.3K ﹤0.01% 2239
2022
Q1 		$690K Buy
31,421
+5,104
+19% +$103K ﹤0.01% 2265
2021
Q4 		$748K Sell
26,317
-70
-0.3% -$1.73K ﹤0.01% 2224
2021
Q3 		$555K Sell
26,387
-5,135
-16% -$107K ﹤0.01% 2404
2021
Q2 		$594K Buy
31,522
+6,722
+27% +$118K ﹤0.01% 2502
2021
Q1 		$379K Hold
24,800
– – ﹤0.01% 2567
2020
Q4 		$350K Hold
24,800
– – ﹤0.01% 2518
2020
Q3 		$389K Hold
24,800
– – ﹤0.01% 2336
2020
Q2 		$434K Buy
24,800
+12,100
+95% +$206K ﹤0.01% 2290
2020
Q1 		$187K Hold
12,700
– – ﹤0.01% 2490
2019
Q4 		$319K Hold
12,700
– – ﹤0.01% 2515
2019
Q3 		$191K Hold
12,700
– – ﹤0.01% 2794
2019
Q2 		$318K Buy
12,700
+8,600
+210% +$213K ﹤0.01% 2594
2019
Q1 		$93K Hold
4,100
– – ﹤0.01% 2970
2018
Q4 		$123K Buy
+4,100
New +$115K ﹤0.01% 2902

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

New York State Common Retirement Fund's CRNX Position: Q2 2026 in Review

New York State Common Retirement Fund increased its Crinetics Pharmaceuticals (CRNX) stake by 4% in Q2 2026, buying an estimated $208K and bringing the position to 147,218 shares worth $5.51M. The position accounts for 0.01% of the portfolio, ranked #1039.

New York State Common Retirement Fund first reported a position in CRNX in Q4 2018 and has held it in 31 quarters since. The position peaked at $7.95M in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • New York State Common Retirement Fund held 147,218 shares of Crinetics Pharmaceuticals worth $5.51M as of Q2 2026.
  • New York State Common Retirement Fund bought 5,600 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $208K.
  • Crinetics Pharmaceuticals made up 0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #1039 holding.
  • New York State Common Retirement Fund first reported a position in Crinetics Pharmaceuticals in Q4 2018 and has held it in 31 quarters since.
  • New York State Common Retirement Fund's Crinetics Pharmaceuticals position peaked at $7.95M in Q4 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.